Showing 2351-2360 of 3223 results for "".
- FDA Authorizes Lilly’s Antibody Therapy Bamlanivimab for Recently Diagnosed COVID-19https://modernod.com/news/fda-authorises-lillys-antibody-therapy-bamlanivimab-for-recently-diagnosed-covid-19/2478512/Eli Lilly announced Monday that the FDA has granted its emergency-use authorization (EUA) request for the investigational neutralizing antibody bamlanivimab. The AbCellera-partnered therapy, also known as LY-CoV555, is authorized to treat recently diagnosed, mild-to-moderate COVID-19 in patients
- Retina Consultants of America Announces New Alliancehttps://modernod.com/news/retina-consultants-of-america-announces-new-alliance-2/2478486/Retina Consultants of America (RCA) has added South Carolina-based Palmetto Retina Center (PRC) to its consortium of practices. This is the seventh retina specialty practice to join RCA. Palmetto Retina Center is comprised of five retina specialists across six offices serving South Carolin
- CMS Alerts Providers to Changes to Medicare Advance Loan Repayments, Giving Hospitals More Timehttps://modernod.com/news/cms-alerts-providers-to-changes-to-medicare-advance-loan-repayments-giving-hospitals-more-time/2478399/The Trump administration laid out more information Thursday about how providers facing financial hardship can get help with repaying loans they received through the Medicare Accelerated and Advance Payments Program, according to a FierceHealthcare
- Azar Lays Out Optimistic COVID-19 Vaccine Timeline of 100 Million Doses by End of 2020https://modernod.com/news/azar-lays-out-optimistic-covid-19-vaccine-timeline-of-100-million-doses-by-end-of-2020/2478396/Health and Human Services Secretary Alex Azar was optimistic that the administration could have 100 million doses of a COVID-19 vaccine by the end of the year but did not promise a vaccine approval before election day, according to a FierceHealthcare
- UH Professor Developing New Technology to Detect Lens Elasticity Associated With Presbyopiahttps://modernod.com/news/uh-professor-developing-new-technology-to-detect-lens-elasticity-associated-with-presbyopia/2478372/A University of Houston biomedical researcher is developing new technology that will measure the stiffness of the lens in the eye, which is likely associated with presbyopia. Presbyopia is linked to a stiffening of the crystalline lens. There are currently several invest
- Retina Consultants of America Announces New Alliancehttps://modernod.com/news/retina-consultants-of-america-announces-new-alliance/2478304/VitreoRetinal Surgery PA, based in Minnesota, has joined Retina Consultants of America (RCA). This is the sixth retina specialty practice to join RCA as it continues to expand the company’s footprint across the United States, including California Retina Consultants, Retina Consultants of Housto
- Lilly, Incyte’s Olumiant Cuts Recovery Time When Added to Veklury in Hospitalized COVID-19 Patientshttps://modernod.com/news/lilly-incytes-olumiant-cuts-recovery-time-when-added-to-veklury-in-hospitalized-covid-19-patients/2478281/Eli Lilly and Incyte reported Monday that the JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) met the primary endpoint of the ACTT 2 study by significantly reducing the time to recovery compared to Veklury alone in hospitalized patients w
- Russia’s Approval of Virus Vaccine Greeted With Some Alarmhttps://modernod.com/news/russias-approval-of-virus-vaccine-greeted-with-some-alarm/2478146/Russia on Tuesday became the first country to approve a coronavirus vaccine for use in tens of thousands of its citizens despite international skepticism about injections that have not completed clinical trials and were studied in only dozens of pe
- Omeros Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19https://modernod.com/news/omeros-reports-recovery-and-survival-of-all-patients-in-study-evaluating-narsoplimab-for-treatment-of-covid-19/2478141/Omeros, maker of Omidria (phenylephrine and ketorolac intraocular solution 1%/0.3%) for use during cataract surgery to prevent miosis and reduce postoperative pain, reported the results of a compassionate-use study evaluating narso
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo